Global Non-Hodgkin Lymphoma (NHL) therapeutics market is expected to reach USD14689.31 million in 2026, growing at a CAGR of 10.02% during the forecast period, owing to increasing demand for innovative drugs and novel technologies for the treatment of Non-Hodgkin’s lymphomas (NHL). Improved diagnostic techniques to detect NHL are expected to push the demand for Non-Hodgkin Lymphoma (NHL) market. Furthermore, patent expiry of standard drugs, especially in untapped market is projected to provide profitable growth opportunities for global Non-Hodgkin Lymphoma (NHL) therapeutics market in upcoming years. Also, extensive R&D activities and the US Food and Drug Administration’s approval for chronic lymphocytic leukemia therapy drugs are serving as major growth drivers for the market.

Non-Hodgkin’s lymphoma (NHL) is a type of blood cancer that originates in white blood cells called lymphocytes, which are part of the body’s immune system. It is generally located at lymph nodes but if not treated on time, it might spread to the entire lymphatic system.

Global Non-Hodgkin Lymphoma (NHL) therapeutics market can be segmented based on type of therapy, cell type, drug type, distribution channel, company and region. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. Out of which, hospital pharmacies held the largest market share in 2020 and is estimated to maintain its leading position in the market in the next five years as well, because these therapeutic drugs are mostly dispensed in hospital pharmacies for the hospitalized patients in order to treat them. In terms of cell type, the market is fragmented into B-cell Lymphomas and T-cell Lymphomas. B-cell Lymphomas is the dominant cell type which can be attributed to the fact that B-cell Lymphomas accounts for the majority of Non-Hodgkin Lymphoma cases across the globe. On the other hand, there are smaller number of patients with T-cell Lymphoma as compared to B-cell Lymphomas.

Regionally, North America dominated the global Non-Hodgkin Lymphoma (NHL) therapeutics market in 2020 and is further expected to hold its dominance during the forecast period. High prevalence of Non-Hodgkin lymphoma (NHL) and availability of advanced treatments in the region are acting as key growth drivers for the market. However, Asia-Pacific is anticipated to register the fastest CAGR during the forecast period owing to rising awareness and prevalence of Non-Hodgkin lymphoma (NHL) in the region.

Major companies operating in global Non-Hodgkin Lymphoma (NHL) therapeutics market include AstraZeneca PLC, Baxter International Inc., Bayer AG, Novartis AG, Eli Lilly and Company., Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Sanofi S.A., Merck & Co., Inc., Kyowa Kirin Co., Ltd. and AbbVie Inc., among others. The market players are focusing on R&D activities to enhance their product portfolios and strengthen their position in global market. Besides, large pharmaceutical companies are adopting strategies such as collaborations and acquisitions to further bolster their status in the Non-Hodgkin’s lymphoma therapeutics market.  Also, strong product pipeline of the top players operating in the market, launch of new therapies along with commercialization of new products are other factors which are further expected to drive growth in the forthcoming years.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022–2026

Objective of the Study:

  • To analyze the historical growth in the market size of global Non-Hodgkin Lymphoma (NHL) Therapeutics market from 2016 to 2020.
  • To estimate and forecast the market size of global Non-Hodgkin Lymphoma (NHL) therapeutics market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global Non-Hodgkin Lymphoma (NHL) Therapeutics market based on type of therapy, cell type, drug type, distribution channel, company and regional distribution from 2021 to 2026 and growth rate until 2026.
  • To identify drivers and challenges for global Non-Hodgkin Lymphoma (NHL) therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global Non-Hodgkin Lymphoma (NHL) therapeutics market.
  • To identify and analyze the profile of leading players operating in the global Non-Hodgkin Lymphoma (NHL) therapeutics market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.

TechSci Research calculated global Non-Hodgkin Lymphoma (NHL) therapeutics market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated them through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Non-Hodgkin Lymphoma (NHL) therapeutics drug manufacturers, companies/partners and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to Non-Hodgkin Lymphoma (NHL) therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as Non-Hodgkin Lymphoma (NHL) Therapeutics manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global Non-Hodgkin Lymphoma (NHL) therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Type of Therapy:
    • Immunotherapy
    • Targeted Therapy
    • Chemotherapy
    • Stem Cell Transplant
    • Others
  • Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Cell Type:
    • B-cell Lymphomas
    • T-cell Lymphomas
  • Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Drug Type:
    • Revlimid
    • Rituxan
    • Keytruda
    • Imbruvica
    • Opdivo
    • Others
  • Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Others
  • Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
    • Asia-Pacific
      • China
      • Japan
      • India 
      • Australia
      • South Korea
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Non-Hodgkin Lymphoma (NHL) therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

Profit margin analysis in case of direct and indirect sales channel.

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market

4.    Executive Summary

5.    Voice of Customer

5.1.  Brand Awareness

5.2.  Unmet Needs & Challenges

5.3.  Factors Influencing Drug Purchase

6.    Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)

6.2.2.     By Cell Type (B-cell Lymphomas, T-cell Lymphomas)

6.2.3.     By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)

6.2.4.     By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)

6.2.5.     By Company (2020)

6.2.6.     By Region

6.3.  Product Market Map

7.    North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type of Therapy

7.2.2.     By Cell Type

7.2.3.     By Drug Type

7.2.4.     By Distribution Channel

7.2.5.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type of Therapy

7.3.1.2.2.             By Cell Type

7.3.1.2.3.             By Drug Type

7.3.1.2.4.             By Distribution Channel

7.3.2.     Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type of Therapy

7.3.2.2.2.             By Cell Type

7.3.2.2.3.             By Drug Type

7.3.2.2.4.             By Distribution Channel

7.3.3.     Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type of Therapy

7.3.3.2.2.             By Cell Type

7.3.3.2.3.             By Drug Type

7.3.3.2.4.             By Distribution Channel

8.    Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type of Therapy

8.2.2.     By Cell Type

8.2.3.     By Drug Type

8.2.4.     By Distribution Channel

8.2.5.     By Country

8.3.  Europe: Country Analysis

8.3.1.     Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type of Therapy

8.3.1.2.2.             By Cell Type

8.3.1.2.3.             By Drug Type

8.3.1.2.4.             By Distribution Channel

8.3.2.     United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type of Therapy

8.3.2.2.2.             By Cell Type

8.3.2.2.3.             By Drug Type

8.3.2.2.4.             By Distribution Channel

8.3.3.     France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type of Therapy

8.3.3.2.2.             By Cell Type

8.3.3.2.3.             By Drug Type

8.3.3.2.4.             By Distribution Channel

8.3.4.     Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Type of Therapy

8.3.4.2.2.             By Cell Type

8.3.4.2.3.             By Drug Type

8.3.4.2.4.             By Distribution Channel

8.3.5.     Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Type of Therapy

8.3.5.2.2.             By Cell Type

8.3.5.2.3.             By Drug Type

8.3.5.2.4.             By Distribution Channel

9.    Asia-Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type of Therapy

9.2.2.     By Cell Type

9.2.3.     By Drug Type

9.2.4.     By Distribution Channel

9.2.5.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type of Therapy

9.3.1.2.2.             By Cell Type

9.3.1.2.3.             By Drug Type

9.3.1.2.4.             By Distribution Channel

9.3.2.     Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type of Therapy

9.3.2.2.2.             By Cell Type

9.3.2.2.3.             By Drug Type

9.3.2.2.4.             By Distribution Channel

9.3.3.     India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type of Therapy

9.3.3.2.2.             By Cell Type

9.3.3.2.3.             By Drug Type

9.3.3.2.4.             By Distribution Channel

9.3.4.     Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Type of Therapy

9.3.4.2.2.             By Cell Type

9.3.4.2.3.             By Drug Type

9.3.4.2.4.             By Distribution Channel

9.3.5.     South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Type of Therapy

9.3.5.2.2.             By Cell Type

9.3.5.2.3.             By Drug Type

9.3.5.2.4.             By Distribution Channel

10.  South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type of Therapy

10.2.2.  By Cell Type

10.2.3.  By Drug Type

10.2.4.  By Distribution Channel

10.2.5.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type of Therapy

10.3.1.2.2.           By Cell Type

10.3.1.2.3.           By Drug Type

10.3.1.2.4.           By Distribution Channel

10.3.2.  Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type of Therapy

10.3.2.2.2.           By Cell Type

10.3.2.2.3.           By Drug Type

10.3.2.2.4.           By Distribution Channel

10.3.3.  Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type of Therapy

10.3.3.2.2.           By Cell Type

10.3.3.2.3.           By Drug Type

10.3.3.2.4.           By Distribution Channel

11.  Middle East and Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Type of Therapy

11.2.2.  By Cell Type

11.2.3.  By Drug Type

11.2.4.  By Distribution Channel

11.2.5.  By Country

11.3.              MEA: Country Analysis

11.3.1.  South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Type of Therapy

11.3.1.2.2.           By Cell Type

11.3.1.2.3.           By Drug Type

11.3.1.2.4.           By Distribution Channel

11.3.2.  Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Type of Therapy

11.3.2.2.2.           By Cell Type

11.3.2.2.3.           By Drug Type

11.3.2.2.4.           By Distribution Channel

11.3.3.  UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Type of Therapy

11.3.3.2.2.           By Cell Type

11.3.3.2.3.           By Drug Type

11.3.3.2.4.           By Distribution Channel

12.  Market Dynamics

12.1.              Drivers

12.2.              Challenges

13.  Market Trends & Developments

14.  Clinical Trial Analysis

15.  Competitive Landscape

15.1.              Competition Outlook

15.2.              Players Profiled (Leading Companies)

15.2.1.  AstraZeneca PLC

15.2.2.  Baxter International Inc.

15.2.3.  Bayer AG

15.2.4.  Novartis AG

15.2.5.  Eli Lilly and Company.

15.2.6.  Spectrum Pharmaceuticals, Inc.

15.2.7.  Teva Pharmaceutical Industries Ltd.

15.2.8.  Bristol Myers Squibb Company

15.2.9.  GlaxoSmithKline PLC

15.2.10. Janssen Pharmaceuticals, Inc.

15.2.11. F. Hoffmann-La Roche Ltd

15.2.12. Sanofi S.A.

15.2.13. Merck & Co., Inc.

15.2.14. Takeda Pharmaceutical Company Limited

15.2.15. AbbVie Inc.

16.  Strategic Recommendations

17.  About Us & Disclaimer

  • Figure 1: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 2: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 3: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 4: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 5: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 6: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Company, 2020

    Figure 7: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Region, By Value, 2016-2026F

    Figure 8: Global Non-Hodgkin Lymphoma (NHL) Therapeutics Product Market Map, By Value, 2016-2026F

    Figure 9: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 10: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 11: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 12: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 13: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 14: North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F

    Figure 15: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 16: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 17: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 18: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 19: United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 20: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 21: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 22: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 23: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 24: Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 25: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 26: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 27: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 28: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 29: Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 30: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 31: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 32: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 33: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 34: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 35: Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F

    Figure 36: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 37: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 38: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 39: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 40: Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 41: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 42: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 43: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 44: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 45: United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 46: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 47: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 48: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 49: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 50: France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 51: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 52: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 53: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 54: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 55: Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 56: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 57: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 58: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 59: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 60: Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 61: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 62: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 63: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 64: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 65: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 66: Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F

    Figure 67: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 68: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 69: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 70: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 71: China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 72: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 73: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 74: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 75: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 76: Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 77: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 78: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 79: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 80: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 81: India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 82: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 83: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 84: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 85: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 86: Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 87: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 88: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 89: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 90: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 91: South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 92: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 93: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 94: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 95: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 96: South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F

    Figure 97: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 98: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 99: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 100: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 101: Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 102: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 103: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 104: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 105: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 106: Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 107: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 108: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 109: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 110: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 111: Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 112: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 113: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 114: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 115: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 116: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 117: Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Country, By Value, 2016-2026F

    Figure 118: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 119: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 120: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 121: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 122: South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 123: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 124: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 125: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 126: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 127: Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F

    Figure 128: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Size, By Value (USD Million), 2016-2026F

    Figure 129: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Type of Therapy, By Value, 2016-2026F

    Figure 130: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Cell Type, By Value, 2016-2026F

    Figure 131: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Drug Type, By Value, 2016-2026F

    Figure 132: UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Share, By Distribution Channel, By Value, 2016-2026F